Tomas Hode, PhD, Co-Founder, CIO, and President of Immunophotonics, Inc. will be attending the SIO2025 Annual Scientific Meeting January 30 to February 3, 2025, in Las Vegas, Nevada.

Tomas will be connecting with interventional oncology professionals from around the world on the latest developments in improving cancer care alongside medical, surgical and radiation oncology to discuss our recent progress in developing IP-001, with the ultimate objective of making IP-001 a potential first-in-class molecule to patients in need.

Look for Tomas at booth #204 at this event and discover how Immunophotonics is pioneering Interventional Immuno-Oncology®, a novel intratumoral immunotherapy designed to reduce tumor recurrence after standard tumor ablation therapy.